On August 22 it was announced that the Pharmaceutical Benefits Advisory Committee (PBAC) deferred their recommendation on Alyftrek as the Therapeutic Goods Administration (TGA) approval process is not yet complete.
Jo Watson, Deputy Chair of the PBAC said:
“The TGA Delegate’s Overview is required before PBAC can provide further advice and a final recommendation for Alyftrek. Once this is provided to the Committee by the TGA, the PBAC will be asked to consider at a future meeting. Once this information is available, the PBAC will be keen to reconsider the item under deferral as soon as possible“.
Here is what you need to know:
A parallel TGA and PBAC process is in place to bring this medicine to Australia as quickly as possible. Unfortunately, one process has moved slightly ahead of the other. In this case, the TGA requires some more time.
- Cystic Fibrosis Australia are urging the PBAC to include Alyftrek at its 5th September intracycle meeting.
- We know our strong community advocacy was recognised and you have been heard. Thank you for partnering with us in this important advocacy work.
As your Peak National Body, Cystic Fibrosis Australia will continue to relentlessly advocate for the urgent listing of Alyftrek.
Learn more about the PBAC/TGA Parallel Process here.